Stockscreener 앱 받기
4.755
16.58%
-0.945
시간 외 거래:
4.80
0.045
+0.95%
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Recursion Pharmaceuticals: Q1 Earnings Snapshot - CTPost
Recursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges - TipRanks
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Mitrade
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Strategic Focus - GuruFocus
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
Recursion Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
AI specialist Recursion trims pipeline in latest shakeup - BioPharma Dive
Why Recursion Pharmaceuticals Stock Was Getting Mashed On Monday - Barchart.com
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com India
Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down - Nasdaq
Document - SEC.gov
Recursion Pharmaceuticals earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases - marketscreener.com
Recursion Pharmaceuticals Reports Q1 Results and Strategy Update - TipRanks
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial - marketscreener.com
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings (NASDAQ:RXRX) - Seeking Alpha
Recursion (RXRX) Reports Promising Results for FAP Treatment - GuruFocus
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | RXRX Stock News - GuruFocus
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - GlobeNewswire Inc.
Recursion Pharmaceuticals (RXRX) Set to Release Q1 Earnings - GuruFocus
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - MSN
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - Bluefield Daily Telegraph
TechBio Pioneer Recursion Announces Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Recursion (RXRX) to Reveal Promising Data on REC-4881 for FAP Tr - GuruFocus
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know - MSN
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - marketscreener.com
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - marketscreener.com
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - Insider Monkey
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
0.39%
3.66%
자본화:
|
볼륨(24시간):